ArticleThe journal of headache and pain2024

Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population.

Carlos Lazaro-Hernandez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.